Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.31 |
| ▸ | GPX4 | P36969 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.30 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24259582 | 0.86 | MAPT (0.35) | HDAC1HDAC6HDAC8MAPTHDAC5 | |
| SCHEMBL22350261 | 0.86 | HDAC1 (0.32) | HDAC1HDAC6HDAC8MAPT | |
| SCHEMBL24259050 | 0.85 | NR1H4 (0.49) | NR1H4 | |
| SCHEMBL24259465 | 0.84 | NR1H4 (0.35) | NR1H4 | |
| SCHEMBL24258908 | 0.84 | NR1H4 (0.34) | NR1H4 | |
| SCHEMBL22353640 | 0.83 | NR1H4 (0.35) | NR1H4 | |
| SCHEMBL24259316 | 0.82 | MAPT (0.36) | HDAC1HDAC8MAPTNR1H4GPX4 | |
| SCHEMBL24602563 | 0.80 | POLB (0.31) | MAPTGPX4 | |
| SCHEMBL24258927 | 0.80 | MAPT (0.34) | HDAC1HDAC6HDAC8MAPTNR1H4 | |
| SCHEMBL22354000 | 0.80 | NR1H4 (0.30) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | HDAC1 641/4885HDAC6 411/4885HDAC8 1194/4885 |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | HDAC1 641/4885HDAC6 411/4885HDAC8 1194/4885 |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | HDAC1 998/4885HDAC6 477/4885HDAC8 995/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | HDAC1 998/4885HDAC6 477/4885HDAC8 995/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | HDAC1 998/4885HDAC6 477/4885HDAC8 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.